Elisabetta Abruzzese

Featured in: Favicon

nature.com Favicon

tandfonline.com Favicon

thelancet.com Favicon

futuremedicine.com Favicon

targetedonc.com Favicon

internationaljournalofcardiology.com Favicon

onlinelibrary.wiley.com

Articles

Correction: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials - Leukemia

Sep 2, 2024 | nature.com | Elias Jabbour |Jane F. Apperley |Jorge Cortés |Michael Deininger |Elisabetta Abruzzese |Daniel DeAngelo | +2 more

Correction to: Leukemia https://doi.org/10.1038/s41375-024-02159-0, published online 29 January 2024Following publication of the article, the authors realized that several data points in Figure S3B and the accompanying manuscript text were incorrect. This oversight has been addressed and the corrected figure has been added. 1.
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials - Leukemia

Jan 29, 2024 | nature.com | Elias Jabbour |Jane F. Apperley |Jorge Cortés |Michael Deininger |Elisabetta Abruzzese |Daniel DeAngelo | +2 more

AbstractPonatinib, the only approved all known-BCR::ABL1 inhibitor, is a third-generation tyrosine-kinase inhibitor (TKI) designed to inhibit BCR::ABL1 with or without any single resistance mutation, including T315I, and induced robust and durable responses at 45 mg/day in patients with CP-CML resistant to second-generation TKIs in the PACE trial.
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib - Blood Cancer Journal

May 3, 2023 | nature.com | Francesca Palandri |Massimiliano Bonifacio |Mario Tiribelli |Alessia Tieghi |Alessandra Iurlo |Nicola Polverelli | +8 more

IntroductionThe coronavirus disease 2019 (Covid19) pandemic caused by the spreading of the coronavirus SARS-CoV-2 has led to substantial mortality in patients with hematological diseases [1].

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →